

CURRICULUM VITAE

PERSONAL INFORMATION:

Name: Jen Jen Yeh, MD, FACS

Work Address: Dept. of Surgery, CB 7213, 170 Manning Dr.
1150 Houpt Physicians Office Bldg., Chapel Hill, NC 25799-7213

Telephone #: Office (919) 966-5221 Fax (919) 966-8806

Home Address: [REDACTED]

Home Telephone: [REDACTED]

EDUCATION:

Fellow Memorial-Sloan Kettering Cancer Center, New York, NY, 2003 - 2005,
Surgical Oncology

Research Fellow Dana-Farber Cancer Institute and Department of Medicine, Harvard
Medical School, Boston, MA, 1998 – 2002, Department of Adult
Oncology (PIs Charis Eng, PhD; William R Sellers, MD)

Resident Boston Medical Center, Boston, MA, 1997 – 2003, General Surgery

M.D. Johns Hopkins University School of Medicine, Baltimore, MD, 1996

B.A. Wesleyan University, Middletown, CT (Biology, magna cum laude),
1991

PROFESSIONAL EXPERIENCE – EMPLOYMENT HISTORY:

Director Pancreatic Cancer Center of Excellence, Lineberger Comprehensive Cancer
Center, University of North Carolina, Chapel Hill, NC, 2019-present

Co-Associate Director Lineberger Comprehensive Cancer Center, University of North
Education Carolina, Chapel Hill, NC, 2019-present

Co-Program Leader Clinical Research Program, Lineberger Comprehensive Cancer Center,
University of North Carolina, Chapel Hill, NC, 2018-present

Professor Department of Pharmacology, University of North Carolina, Chapel Hill,
NC, 2017-present

Professor Department of Surgery, University of North Carolina, Chapel Hill, NC,
2017-present

Vice Chair Department of Surgery, University of North Carolina, Chapel Hill, NC,
for Research 2015-present

Associate Fellowship Program Director	Complex Surgical Oncology Fellowship, University of North Carolina, Chapel Hill, NC, 2015-present
Interim Division Chief	Division of Gastrointestinal Surgery, Department of Surgery, University of North Carolina, Chapel Hill, NC, 2019-2020
Associate Professor	Department of Pharmacology, University of North Carolina, Chapel Hill, NC, 2011-2017
Associate Professor	Department of Surgery, University of North Carolina, Chapel Hill, NC, 2011-2017
Member	Genetics and Molecular Biology Curriculum, University of North Carolina, Chapel Hill, NC, 2010-2018
Assistant Professor	Department of Pharmacology, University of North Carolina, Chapel Hill, NC, 2010-2011
Assistant Professor	Department of Surgery, University of North Carolina, Chapel Hill, NC, 2005-2011
Research Technician	Dana-Farber Cancer Institute, Boston, MA, 1991-1992 (PI William G. Kaelin Jr.)

LICENSURE:

2005-	North Carolina State License No. 2005-01489
1996 - 2002	Massachusetts Limited License, No. 4734
2003 - 2005	New York State License No. 228047
2004 -	Diplomat, American Board of Surgery

HONORS AND AWARDS:

2023	Carolina Care Excellence Award
2020	AACR Team Science Award
2019	DSR Sarma Lectureship in Oncologic Pathology. University of Toronto.
2018	Peter J. Mozden, MD Visiting Professorship in Surgical Oncology, Boston Medical Center
2017-present	Oliver Smithies Investigator
2017	Third Annual Feeny Distinguished Lecturer in HPB Surgical Oncology, University of Toronto.
2016	UNC Chancellor's Faculty Entrepreneurship Workshop
2015	American Society of Clinical Investigation
2012	Society of Surgical Oncology Clinical Investigator Award
2009	American Surgical Association Foundation Fellowship Award
2008	Franklin H. Martin, MD, FACS, Faculty Research Fellowship of the American College of Surgeons
2008	Kimmel Translational Scholar Award
2008	University Cancer Research Fund Translational Award

2007	Emerald Foundation Award
2007	UNC GI SPORE Career Development
2007	UNC Lineberger Comprehensive Cancer Center Clinical/Translational Award
2007	University Research Council Award
2007	NIH Loan Repayment Program Award
2007	Program in Translational Science Award
2006	ASCO Young Investigator Award
2006	NIH K12 Mentored Research Scholar Career Development Program, Scholar
2005	Gorin Fellow Award, Memorial Sloan-Kettering Cancer Center
2005	ASCO Foundation Merit Award
2005	UNC GI SPORE Career Development Award
2002	Alpha Omega Alpha, Membership
2000	Sixth Annual Surgical Research Symposium, Third Place, New England Medical Center Hospital, MA
2000	Sigma Xi, Membership
1999	Daland Resident Award, New England Cancer Society, Providence, RI
1999	Bayer Speaking for Excellence Competition, Second Place, Fifth Annual Surgical Research Symposium, New England Medical Hospital, MA
1998	Resident Award for Excellence in Critical Care, Boston Medical Center
1989-1991	Wesleyan Honors recital
1989-1991	Research Fellowships, Howard Hughes Program in the Life Sciences
1989	Wesleyan Concerto Competition, Second Place

BIBLIOGRAPHY:

Book Chapters

1. Kearney JH, Adsay V, **Yeh JJ**. Pathology and molecular characteristics of pancreatic cancer. *Surg Oncol Clin N Am*. 2021 Oct; 30(4):609-619.
2. Nayyar A and **Yeh JJ**. Understanding the genetics of pancreatic adenocarcinoma. In: Cance WG and Hochwald SN (eds). *Complex General Surgical Oncology. Decker Intellectual Properties 2017*.
3. Purcell LN and **Yeh JJ**. Molecular Genetics of Thyroid Cancer. In: Mancino AT and Kim LT (eds). *Management of Differentiated Thyroid Cancer. Springer International Publishing 2017 p. 15*.
4. Lopez NE and **Yeh JJ**. Gastrointestinal malignancy: genetic implications to clinical applications. In: Bentrem DJ and Benson AB (eds). *Gastrointestinal Malignancies. Springer International Publishing 2016 p. 393*.
5. **Yeh JJ**, Madigan JP, Campbell PM, DeGraffenreid L, Der CJ. Targeting Ras for anti-cancer drug discovery. In: Bradshaw RA, Dennis EA (eds). *The Handbook of Cell Signaling Volume 3. Academic Press 2007 Chapter 329 pp. 2837-2857*.
6. **Yeh JJ** and Sellers WR. Editor Fisher DE. "PTEN: a regulator of phosphoinositide 3-kinase signal transduction" in Tumor Suppressor Genes in Cancer Therapy. *The Humana Press, Inc. 2001 Chapter 10 pp. 231-251*.

Reviews/Perspectives

1. Kearney JF, Weighill D, **Yeh JJ**. Promise of bile circulating tumor DNA in biliary tract cancers. *Cancer*. 2023 June 1:129(11);1643-1645. Epub 2023 Mar 18. PMID: 36932988.
2. Perez, VP, Kearney JF, **Yeh JJ**. The PDAC Extracellular Matrix: A Review of the ECM Protein Composition, Tumor Cell Interaction, and Therapeutic Strategies. *Front Oncol* 2021 Oct 6:11: 4114. <https://doi.org/10.3389/fonc.2021.751311> eCollection 2021 PMID: 34692532
3. Kearney JF, Adsay V, **Yeh JJ**. Pathology and molecular characteristics of pancreatic cancer. *Surg Oncol Clin N AM*. 2021 Oct;30(4):609-619. doi: 10.1016/j.soc.2021.06.003. Epub 2021 Jul 22. PMID: 34511185.
4. Weighill D, Ben Guebila M, Glass K, Platig J, **Yeh JJ**, Quackenbush J. Gene targeting in disease networks. *Front Genet* 2021 Apr 23;12:649942. doi.org/10.3389/fgene.2021.649942. eCollection 2021. PMID: 33968133.
5. Byrne JD, **Yeh JJ**, DeSimone JM. Use of iontophoresis for the treatment of cancer. *J doi: 10.1016/j.jconrel.2018.06.020*. Epub 2018 Jun 15. PMID: 29908892.
6. Lipner MB, **Yeh JJ**. Sequencing pancreatic juice: squeezing the most out of surveillance. *Clinical Cancer Research* 2018 Jun 15;24(12):2713-2715. doi: 10.1158/1078-0432.CCR-18-0215. Epub 2018 Mar 2. PMID: 29500277.
7. Lopez NE, **Yeh JJ**. Gastrointestinal malignancy: Genetic implications to clinical applications. *Cancer Treat Res*. 2016;168:393-479. doi: 10.1007/978-3-319-34244-3_19. PMID: 29206386.
8. **Yeh JJ**, Kim WY. Targeting tumor hypoxia. *J Clin Oncol*. 2015 May 1;33(13):1505-8. doi: 10.1200/JCO.2014.60.0759. Epub 2015 Mar 23. PMID: 25800764.
9. **Yeh JJ**. A prognostic signature in pancreatic cancer: are we close? *Future Oncology*. 2009 Apr; 5(3):313-21. Review.
10. **Yeh JJ**, Der CJ. Targeting signal transduction in pancreatic cancer treatment. *Expert Opinion on Therapeutic Targets*. 2007 May; 11(5) 673-94. Review.

In Refereed Journals

1. Leary JR, Xu Y, Morrison AB, Jin C, Shen EC, Kuhlers PC, Su Y, Rashid NU, **Yeh JJ**, Peng XL. Sub-Cluster identification through semi-supervised optimization of rare-cell silhouettes (SCISSORS) in single-cell RNA-sequencing. *Bioinformatics* 2023 Aug 1; 39(8):btad449. PMC10412410.
2. Maduekwe UN, Stephenson BJK, **Yeh JJ**, Troester MA, Sanoff HK. Identifying patient profiles of disparate care in resectable pancreas cancer using latent class analysis. *J Surg Oncol*. 2023 Aug;128(2);254-261. Epub 2023 Apr 24. PMID: 37095707.
3. Torre-Healy LA, Kawalerski RR, Oh K, Chrastecka L, Peng XL, Aguirre AJ, Rashid NU, **Yeh JJ**, Moffitt RA. Open-source curation of a pancreatic ductal adenocarcinoma gene expression analysis platform (pdacR) supports a two-subtype model. *Commun Biol* 2023 Feb 10;6(1):163. PMID: 36765128.
4. Mirlekar B, Wang Y, Li S, Zhou M, Entwistle S, De Buysscher T, Morrison A, Hererra G, Harris C, Vincent BG, Ting JP, Rashid N, Kim WY, **Yeh JJ**, Pylayeva-Gupta Y. Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. *Cell Rep Med* 2022 Sep 20; 3(9):100744. Epub 2022 Sept 12. PMID: 3609917. PMC9512696
5. Rajesh C, Sagar S, Rathinavel AK, Chemparathy DT, Peng XL, **Yeh JJ**, Hollingsworth MA, Radhakrishnan P. Truncated O-glycan-bearing MUC16 enhances pancreatic cancer cells aggressiveness via alpha-4-beta-1 integrin complexes and FAK signaling. *Int J Mol Sci* 2022 May 13; 23(10):5459. PMID 35628269 PMC9141077
6. Cook DR, Kang M, Martin TD, Galanko JA, Loeza GH, Trembath DG, Justilien V, Pickering KA, Vincent DF, Jarosch A, Jurmeister P, Waters AM, Hibshman PS, Campbell AD, Ford CA,

- Keku TO, **Yeh JJ**, Lee MS, Cox AD, Fields AP, Sandler RS, Sansom OJ, Sers C, Schaefer A, Der CJ. Aberrant expression and subcellular localization of ECT2 drives colorectal cancer progression and growth. *Cancer Res* 2022 Jan 1; 82(1): 90-104. Epub 2021 Nov 4. PMID: 34737214.
7. Gebregiworgis T, Kano Y, St-Germain J, Radulovich N, Udaskin ML, Menten A, Huang R, Poon BPK, He W, Valencia-Sama I, Robinson CM, Huestis M, Miao J, **Yeh JJ**, Zhang ZY, Irwin MS, Lee JE, Tsao MS, Raught B, Marshall CB, Ohh M, Ikura M. The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2. *Nat Commun*. 2021 Nov 1; 12(1) 6274. PMID 34725361 PMC8560773
 8. Rashid, NU, Lockett DJ, Chen J, Lawson MT, Wang L, Zhang Y, Laber EB, Liu Y, **Yeh JJ**, Zeng D, Kosorok MR. High-dimensional precision medicine from patient-derived xenografts. *J Am Stat Assoc*. 2021. 116(535):1140-1154 doi: 10.1080/01621459.2020.1828091. epub 2020 Nov 12. PMC8451968. PMID:34548714.
 9. Ruffolo LI, Jackson KM, Kuhlers PC, Dale BS, Figueroa Guilliani NM, Ullman NA, Burchard PR, Qin SS, Juviler PG, Keilson JM, Morrison AB, Georger M, Jewell R, Calvi LM, Nywening TM, O'Dell MR, Hezel AF, De Las Casas L, Lesinski GB, **Yeh JJ**, Hernandez-Alejandro R, Belt BA, Linehan DC. GM-CSF drives myelopoiesis, recruitment and polarization of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity. *Gut*. 2022 Jul;71(7):1386-1398. doi: 10.1136/gutjnl-2021-324109. Epub 2021 Aug 19. PMID: 34413131.
 10. Hendley AM, Rao AA, Leonhardt L, Ashe S, Smith JA, Giacometti S, Peng XL, Jiang H, Berrios DI, Pawlak M, Li LY, Lee J, Collisson EA, Anderson MS, Fragiadakis GK, **Yeh JJ**, Ye CJ, Kim GE, Weaver VM, Hebrok M. Single-cell transcriptome analysis defines heterogeneity of the murine pancreatic ductal tree. *Elife*. 2021 May 19;10:e67776. doi: 10.7554/eLife.67776. PMID: 34009124
 11. Thomas D, Sagar S, Liu X, Lee HR, Grunkemeyer JA, Grandgenett PM, Caffrey T, O'Connell KA, Swanson B, Marcos-Silva L, Steentoft C, Wandall HH, Maurer HC, Peng XL, **Yeh JJ**, Qiu F, Yu F, Madiyalakan R, Olive KP, Mandel U, Clausen H, Hollingsworth MA, Radhakrishnan P. Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer. *Mol Ther* 2021 Apr 7;29(4):1557-1571. doi: 10.1016/j.ymthe.2020.12.029. Epub 2020 Dec 25. PMC8058431. PMID: 33359791
 12. Rashid NU, Li Q, **Yeh JJ**, Ibrahim JG. Modeling between-study heterogeneity for improved replicability in gene signature selection and clinical prediction. *J Am Stat Assoc*. 2020;115(531):1125-1138. doi: 10.1080/01621459.2019.1671197. Epub 2019 Oct 29. PMID: 33012902.
 13. Jiang H, Torphy RJ, Steiger K, Hongo H, Ritchie AJ, Kriegsmann M, Horst D, Umetsu SE, Joseph NM, McGregor K, Pishvaian MJ, Blais EM, Lu B, Li M, Hollingsworth M, Stashko C, Volmar K, **Yeh JJ**, Weaver VM, Wang ZJ, Tempero MA, Weichert W, Collisson EA. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. *J Clin Invest*. 2020 Sep 1;130(9):4704-4709. doi: 10.1172/JCI136760. PMID: 32749238
 14. N'Guessan KF, Davis HW, Chu Z, Vallabhapurapu SD, Lewis CS, Franco RS, Olowokure O, Ahmad SA, **Yeh JJ**, Bogdanov VY, Qi X. Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-targeted Nanovesicles against Pancreatic Cancer. *Mol Ther*. 2020 Aug 5;28(8):1876-1886. doi: 10.1016/j.ymthe.2020.05.013. Epub 2020 June 8. PMID: 32516572
 15. Lipner MB, Peng XL, Jin C, Xu Y, Gao Y, East MP, Rashid NU, Moffitt RA, Herrera Loeza SG, Morrison AB, Golitz BT, Vaziri C, Graves LM, Johnson GL, **Yeh JJ**. Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy. *JCI Insight*. 2020 Apr 23;5(8):e129905. doi: 10.1172/jci.insight.129905. PMID: 32213714
 16. Mirlekar B, Michaud D, Lee SJ, Kren NP, Harris C, Greene K, Goldman EC, Gupta GP, Fields RC, Hawkins WG, DeNardo DG, Rashid NU, **Yeh JJ**, McRee AJ, Vincent BG, Vignali DAA,

- Pylayeva-Gupta Y. B cell-Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer. *Cancer Immunol Res.* 2020 Mar;8(3):292-308. doi: 10.1158/2326-6066.CIR-19-0349. Epub 2020 Feb 5. PMID: 32024640.
17. Rashid NU, Peng XL, Jin C, Moffitt RA, Volmar KE, Kawalerski R, Belt BA, Panni RZ, Nywening TM, Herrera SG, Moore KJ, Hennessey S, Morrison AB, Nayyar A, Change AE, Schmidt B, Kim HJ, Linehan DC, **Yeh JJ**. Purity independent subtyping of tumors (PurIST), a clinically robust single sample classifier for tumor subtyping in pancreatic cancer. *Clin Cancer Res*, 2020, Jan 1;26(1):82-92. Epub 2019 Nov 21. PMID: 31754050.
 18. Peng XL, Moffitt RA, Torphy RJ, Volmar KE, **Yeh JJ**. De novo compartment deconvolution and weight estimation of tumor samples using DECODER. *Nature Commun*, 2019, Oct 18;10(1):4729. doi: 10.1038/s41467-019-12517-7. PMID: 31628300.
 19. Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, Tiruthani K, Mirlekar R, Michaud D, Greene K, Herrera SG, Xu Y, Sun C, Chen Y, Ma X, Ferrone CR, Pylayeva-Gupta Y, **Yeh JJ**, Liu R, Savoldo B, Ferrone S, Dotti G. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. *Cancer Cell* 2019, Feb 11;35(2):221-237.e8. doi: 10.1016/j.ccell.2019.01.002. PMID: 30753824.
 20. Kano Y, Gebregiworgis T, Marshall CB, Radulovich N, Poon BPK, St-Germain J, Cook JD, Valencia-Sama I, Grant BMM, Herrera SG, Miao J, Raught B, Irwin MS, Lee JE, **Yeh JJ**, Zhang ZY, Tsao MS, Ikura M, Ohh M. Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and switch II conformation. *Nat Commun.* 2019 Jan 15;10(1):224. doi: 10.1038/s41467-018-08115-8. PMID: 30644389.
 21. Torphy RJ, Wang Z, True-Yasaki A, Volmar KE, Rashid N, Yeh B, Johansen JS, Hollingsworth MA, **Yeh JJ***, Collisson EA*. Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma. *JCO Precision Oncology* 2018(2):1-12. PO.17.00121. doi: 10.1200/PO.17.00121. Epub 2018 Jan 16. PMID: 30506016
*Equal contribution
 22. Cools KS, Sanoff HK, Kim HJ, **Yeh JJ**, Stitzenberg KB. Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy. *J Surg Oncol* 2018 Sep;188(3):455-462. doi: 10.1002/jso.25183. Epub 2018 Aug 16. PMID: 30114330.
 23. Innocenti F, Owzar K, Jiang C, Etheridge AS, Gordân R, Sibley AB, Mulkey F, Niedzwiecki D, Glubb D, Neel N, Talamonti MS, Bentrem DJ, Seiser E, **Yeh JJ**, Van Loon K, McLeod H, Ratain MJ, Kindler HL, Venook AP, Nakamura Y, Kubo M, Petersen GM, Bamlet WR, McWilliams RR. The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. *PLoS One* 2018 Aug 14;13(8):30202272. doi: 10.1371/journal.pone.0202272. eCollection 2018. PMID: 30107003.
 24. Danai LV, Babic A, Rosenthal MH, Dennstedt EA, Muir A, Lien EC, Mayers JR, Tai K, Lau AN, Jones-Sali P, Prado CM, Petersen GM, Takahashi N, Sugimoto M, **Yeh JJ**, Lopez N, Bardeesy N, Fernandez-Del Castillo C, Liss AS, Koong AC, Bui J, Yuan C, Welch MW, Brais LK, Kulke MH, Dennis C, Clish CB, Wolpin BM, Vander Heiden MG. Altered exocrine function can drive adipose wasting in early pancreatic cancer. *Nature* 2018 Jun;558(7711):600-604. doi: 10.1038/s41586-018-0235-7. Epub 2018 Jun 20. PMID: 29925948.
 25. Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S, Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, Helvie K, Oliver N, Babic A, Da Silva A, Nadres B, Van Seventer EE, Shahzade HA, St Pierre JP, Burke KP, Clancy TE, Cleary JM, Doyle LA, Jajoo K, McCleary NJ, Meyerhardt JA, Murphy JE, Ng K, Patel AK, Perez K, Rosenthal MH, Rubinson DA, Ryou M, Shpairo GI, Sicinska E, Silverman SG, Nagy RJ, Lanman RB, Knoerzer D, Welsch DJ, Yurgelun MB, Fuchs CS, Garraway LA, Getz G, Hornick JL, Johnson BE, Kulke MH, Mayer RJ, Miller JW, Shyn PB, Tuveson DA, Wagle N, **Yeh JJ**, Hahn WC, Corcoran RB, Carter SL, Wolpin BM.

- Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. *Cancer Discovery* 2018 Sep;8(9):1096-1111. doi: 10.1158/2159-8290.CD-18-0275. Epub 2018 Jun 14. PMID: 29903880.
26. Krulik LJ, McDonald IM, Lee B, Okumu DO, East MP, Gilbert TSK, Herring LE, Golitz BT, Wells CI, Axtman AD, Zuercher WJ, Willson TM, Kireev D, **Yeh JJ**, Johnson GL, Baines AT, Graves LM. Application of integrated drug screening/kinome analysis to identify inhibitors of gemcitabine-resistant pancreatic cancer cell growth. *SLAS Discovery* 2018 Sep;23(8):850-861. doi: 10.1177/2472555218773045. Epub 2018 May 9. PMID: 29742358.
 27. Byrne JD, Jajja MRN, O'Neill AT, Schorzman AN, Keller AW, Luft JC, Zamboni WC, DeSimone JM, **Yeh JJ**. Impact of formulation on iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer. *Cancer Chemotherapy Pharmacology* 2018 Jun;81(6):991-998. doi: 10.1007/s00280-018-3570-3. Epub 2018 Mar 30. PMID: 29603014.
 28. Aung KL, Fischer SE, Denroche RE, Jang GH, Dodd A, Creighton S, Southwood B, Liang SB, Chadwick D, Zhang A, O'Kane GM, Albaba HAA, Moura S, Grant RC, Miller JK, Mbabaali F, Pasternack D, Lungu IM, Bartlett JMS, Ghai S, Lemire M, Holter S, Connor AA, Moffitt RA, **Yeh JJ**, Timms L, Krzyzanowski PM, Dhani NC, Hedley DW, Notta F, Wilson JM, Moore MJ, Gallinger S, Knox JJ. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer - Early Results from the COMPASS Trial. *Clin Cancer Res.* 2018 Mar 15;24(6):1344-1354. doi: 10.1158/1078-0432.CCR-17-2994. Epub 2017 Dec 29. PMID: 29288237.
 29. Laks S, Meyers MO, Deal AM, Frank JS, Stitzenberg KB, **Yeh JJ**, Thomas NE, Ollila DW. Tumor Mitotic Rate and Association with Recurrence in Sentinel Lymph Node Negative Stage II Melanoma Patients. *Am Surg.* 2017 Sep 1;83(9):972-978. PMID: 28958277.
 30. Cancer Genome Atlas Research Network (**Yeh JJ**). Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. *Cancer Cell.* 2017 Aug 14;32(2):185-203.e13. doi: 10.1016/j.ccell.2017.07.007. PMID: 2881014.
 31. Black J, Cotton T, **Yeh JJ**. Outpatient Total Thyroidectomy Is Safe for Moderate-Volume Surgeons. *Am Surg.* 2017 Jul 1;83(7):750-754. PMID: 28738947
 32. Bailey ST, Smith AM, Kardos J, Wobker SE, Wilson HL, Krishnan B, Saito R, Lee HJ, Zhang J, Eaton SC, Williams LA, Manocha U, Peters DJ, Pan X, Carroll TJ, Felsher DW, Walter V, Zhang Q, Parker JS, **Yeh JJ**, Moffitt RA, Leung JY, Kim WY. MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma. *Nat Commun* 2017 Jun 8;8:15770. doi: 10.1038/ncomms15770. PMID: 28593993.
 33. Rigoutsos I, Lee SK, Nam SY, Anfossi S, Pasculli B, Pichler M, Jing Y, Rodriguez-Aguayo C, Telonis AG, Rossi S, Ivan C, Catela Ivkovic T, Fabris L, Clark PM, Ling H, Shimizu M, Redis RS, Shah MY, Zhang X, Okugawa Y, Jung EJ, Tsirigos A, Huang L, Ferdin J, Gafa R, Spizzo R, Nicoloso MS, Paranjape AN, Shariati M, Tiron A, **Yeh JJ**, Teruel-Montoya R, Xiao L, Melo SA, Menter D, Jiang ZQ, Iores ER, Negrini M, Goel A, Bar-Eli M, Mani SA, Liu CG, Lopez-Berestein G, Berindan-Neagoe I, Esteller M, Kopetz S, Lanza G, Calin GA. N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. *Genome Biol* 2017 May; 18(1):98. doi: 10.1186/s13059-017-1224-0. PMID: 28535802.
 34. Stratford JK, Yan F, Hill RA, Major MB, Graves LM, Der CJ, **Yeh JJ**. Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability. *PLoS One* 2017 Apr 5; 12(4):e0174863. doi: 10.1371/journal.pone.0174863. eCollection 2017. PMID: 28380042.
 35. Witek MA, Auffort RD, Wang H, Kamande JW, Jackson JM, Pullagurla SW, Hupert ML, Usary J, Wysham WZ, Hilliard D, Montgomery S, Bae-Jump V, Carey LA, Gehrig PA, Milowsky MI, Perou CM, Soper JT, Whang YE, **Yeh JJ***, Martin G*, Soper SA*. Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast

- activation protein alpha and epithelial cell adhesion molecule. *NPJ Precis Oncol.* 2017;1:24. doi: 10.1038/s41698-017-0028-8. Epub 2017 Jul 25. PMID: 29657983. *co-corresponding
36. Welch JD, Williams LA, DiSalvo M, Brandt AT, Marayati R, Sims CE, Allbritton NL, Prins JF, **Yeh JJ***, Jones CD*. Selective single cell isolation for genomics using microraft arrays. *Nucleic Acids Res.* 2016 Sep 30;44(17):8292-301. doi: 10.1093/nar/gkw700. Epub 2016 Aug 16. PMID: 27530426 *co-corresponding
37. Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario Am, Else T, Knijnenburg TA, Ciriello G, Kim S, Assie G, Morozova O, Akbani R, Shih J, Hoadley KA, Choueiri TK, Waldmann J, Mete O, Robertson AG, Wu HT, Raphael BJ, Shao L, Meyerson M, Demeure MJ, Beuschlein F, Gill Aj, Sidhu Sb, Almeida MQ, Fragoso MC, Cope LM, Kebebew E, Habra MA, Whitsett TG, Bussey KJ, Rainey WE, Asa SL, Bertherat J, Fassnacht M, Wheeler DA, **Cancer Genome Atlas Research Network (Yeh JJ)**, Hammer GD, Giordano TJ, Verhaak RGW. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. *Cancer Cell* 2016 Aug 8;30(2):363. doi: 10.1016/j.ccell.2016.07.013. Epub 2016 Aug 8. PMID: 27505681.
38. Anderson M, Marayati R, Moffitt RA, **Yeh JJ**. Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production. *Oncotarget* 2016 Jun 1;8(34):56081-56094. doi: 10.18632/oncotarget.9760. eCollection 2017 Aug 22. PMID: 28915575.
39. Byrne JD, Jajja MR, O'Neill AT, Schorzman AN, Keeler AW, Luft JC, Zamboni WC, DeSimone J*, **Yeh JJ***. Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma. *Proc Natl Acad Sci U S A.* 2016 Feb 23;113(8):2200-5. doi: 10.1073/pnas.1600421113. Epub 2016 Feb 8. PMID: 26858448. *co-corresponding
40. Lipner MB, Marayati R, Deng Y, Wang X, Raftery L, O'Neil BH, **Yeh JJ**. Metformin treatment does not inhibit growth of pancreatic cancer patient-derived xenografts. *PLoS One* 2016 Jan 13;11(1):e0147113. doi: 10.1371/journal.pone.0147113. eCollection 2016. PMID: 26760500.
41. Hayes TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, Marayati R, Kher S, George SD, Petricoin III, EF, Yin HH, Nelkin B, Cox AD, **Yeh JJ**, Der CJ. Long-term ERK inhibition in *KRAS*-mutant pancreatic cancer is associated with MYC degradation and senescence-like growth suppression. *Cancer Cell.* 2016 Jan 11;29(1):75-89. doi: 10.1016/j.ccell.2015.11.011. Epub 2015 Dec 24. PMID: 26725216.
42. Moffitt RA, Marayati R, Volmar KE, Hoadley, KA, Anderson J, Bentrem DJ, Talamonti MS, Iacobuzio-Donahue CA, Hollingsworth MA, **Yeh JJ**. Virtual microdissection of pancreatic ductal adenocarcinoma reveals tumor and stroma subtypes. *Nat Genet.* 2015 Oct;47(10):1168-78. doi: 10.1038/ng.3398. Epub 2015 Sep 7. PMID: 26343385.
43. Allali I, Delgado S, Marron PI, Astudillo A, Yeh JJ, Ghazal H, Amzazi S, Keku T, Azcarate-Peril MA. Gut microbiome compositional and functional differences between tumor and non-tumor adjacent tissues from cohorts from the US and Spain. *Gut Microbes.* 2015;6(3):161-72. doi: 10.1080/19490976.2015.1039223. PMID: 25875428.
44. Londin E, Loher P, Telonis AG, Quann K, Clark P, Jing Y, Hatzimichael E, Kirino Y, Honda S, Lally M, Ramratnam B, Comstock CE, Knudsen KE, Gomella L, Spaeth GL, Hark L, Katz LJ, Witkiewicz A, Rostami A, Jimenez SA, Hollingsworth MA, **Yeh JJ**, Shaw CA, McKenzie SE, Bray P, Nelson PT, Zupo S, Van Roosbroeck K, Keating MJ, Calin GA, Yeo C, Jimbo M, Cozzitorto J, Brody JR, Delgrosso K, Mattick JS, Fortina P, Rigoutsos I.. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. *Proc Natl Acad Sci U S A.* 2015 Mar 10;112(10):E1106-15. doi: 10.1073/pnas.1420955112. Epub 2015 Feb 23..
45. Byrne JD, Jajja MR, O'Neill AT, Bickford LR, Keller AW, Hyder N, Wagner K, Deal AM, Little RE, Moffit RM, Stack C, Nelson M, Brooks CR, Lee W, Luft JC, Napier ME, Darr D,

- Anders CK, Stack RS, Tepper J, Wang AZ, Zamboni WC, **Yeh JJ***, DeSimone J*. Local Iontophoretic Administration of Cytotoxic Therapies to Solid Tumors. *Sci Transl Med.* 2015 Feb 4;7(273):273ra14. doi: 10.1126/scitranslmed.3009951. PMID: 25653220. *co-corresponding
46. Tignanelli CJ, Herrera Loeza SG, **Yeh JJ**. KRAS and PIK3CA mutation frequencies in patient derived xenograft (PDX) models of pancreatic and colorectal cancer are reflective of patient tumors and stable across passages. *American Surgeon* 2014, Sep;80(9):873-7.
 47. Bailey ST, Zhou B, Damrauer JS, Krishnan B, Wilson HL, Smith AM, Li M, **Yeh JJ**, Kim WY. mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma. *PLoS One* 2014, Sep; 9(9):e104413.
 48. Shah PK, Herrera-Loeza SG, Sims CE, **Yeh JJ**, Allbritton NL. Small sample sorting of primary adherent cells by automated micropallet imaging and release. *Cytometry A.* 2014 Jul;85(7):642-9.
 49. Proctor A, Herrera-Loeza SG, Wang Q, Lawrence D, **Yeh JJ**, Allbritton, NL. Measurement of Protein Kinase B Activity in Single Primary Human Pancreatic Cancer Cells. *Anal Chem* 2014, May 6; 86(9):4573-80.
 50. Damrauer JS, Hoadley KA, Chism DD, Fan C, Tignanelli CJ, Wobker SE, **Yeh JJ**, Milowsky MI, Iyer G, Parker JS, Kim WY. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. *Proc Natl Acad Sci USA* 2014 Feb 25;111(8)3110-5.
 51. Torphy RJ, Tigananelli CJ, Kamande JW, Moffitt RA, Herrera Loeza SG, Soper SA, **Yeh JJ**. Circulating Tumor Cells as a Biomarker of Response to Treatment in Patient-Derived Xenograft Mouse Models of Pancreatic Adenocarcinoma. *PLoS One* 2014 Feb 19; 9(2):389474.
 52. Gach PC, Attayek PJ, Whittlesey RL, **Yeh JJ**, Allbritton NL. Micropallet arrays for the capture, isolation and culture of circulating tumor cells from whole blood of mice engrafted with primary human pancreatic adenocarcinoma. *Biosensors and Bioelectronics* 2014 Apr 15;54:476-83.
 53. Neel NF, Stratford JK, Shinde V, Ecsedy JA, Martin TD, Der CJ, **Yeh JJ**. Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation. *Mol Cancer Ther.* 2014 Jan;13(1):122-33.
 54. Kamande JW, Hupert ML, Witek MA, Wang H, Torphy RJ, Dharmasiri U, Njoroge SK, Jackson JM, Aufforth RD, Snavely A, **Yeh JJ**, Soper SA. Modular microsystem for the isolation, enumeration and phenotyping of circulating tumor cells in patients with pancreatic cancer. *Anal Chem* 2013 Oct 1;85(19):9092-100.
 55. Wang Y, Phillips CN, Herrera GS, Sims CE, **Yeh JJ**, Allbritton NL. Array of biodegradable micrafts for isolation and implantation of living, adherent cells. *RSC Adv.* 2013 Jun 3(24):9264-9272.
 56. Jackson JM, Witek MA, Hupert ML, Brady C, Pullagurla S, Kamande J, Aufforth RD, Tignanelli CJ, Torphy RJ, **Yeh JJ**, Soper SA. UV activation of polymeric high aspect ratio microstructures: ramifications in antibody surface loading for circulating tumor cell selection. *Lab Chip* 2014 Jan 7;14(1):106-17.
 57. Gach PC, Attayek PJ, Herrera G, **Yeh JJ**, Allbritton NL. Isolation and in vitro culture of rare cancer stem cells from patient-derived xenografts of pancreatic ductal adenocarcinoma. *Anal Chem* 2013 Aug 6;85(15):7271-8.
 58. Sweeting RS, Dela AM, Llaguna OH, Bednarski BK, Meyers MO, **Yeh JJ**, Calvo BF, Tepper JE, Kim HJ. Intraoperative electron radiation therapy as an important treatment modality in retroperitoneal sarcoma. *J Surg Res.* 2013 Nov;185(1):245-9.
 59. Bang D, Wilson W, Ryan M, **Yeh JJ**, Baldwin AS. GSK-3alpha promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of non-canonical NF-kappaB. *Cancer Discov.* 2013 Jun 3(6):690-703.

60. Streeter JE, Herrera-Loeza SG, Neel NF, **Yeh JJ**, Dayton PA. A comparative evaluation of ultrasound molecular imaging, perfusion imaging and volume measurements in evaluating response to therapy in patient-derived xenografts. *Technol Cancer Res Treat*. Technol Cancer Res Treat. 2013 Aug;12(4):311-21.
61. Goicoechea SM, García-Mata R, Staub J, Valdivia A, Sharek L, McCulloch CG, Hwang RF, Urrutia R, **Yeh JJ**, Kim HJ, Otey CA. Palladin promotes invasion of pancreatic cancer cells by enhancing invadopodia formation in cancer-associated fibroblasts. *Oncogene*. 2013 Mar 6;33(10):1265-73.
62. McCoy AN, Araujo-Perez F, Azcarate-Peril A, **Yeh JJ**, Sandler RS, Keku TO. Fusobacterium is associated with colorectal adenomas. *PLoS One*. 2013 (1)8:e53653.
63. Khandelwal CM, Meyers, MO, **Yeh JJ**, Amos KD, Frank JS, Long P, Ollila DW. Relative value unit impact of complex skin closures to academic surgical melanoma practices. *Am J Surg*. 2012 Sep 204(3):327-31.
64. Wang JG, Geddings JE, Aleman MM, Cardenas JC, Chantrathammachart P, Williams JC, Kirchofer D, Bogdanov VY, Bach RR, Rak J, Church FC, Wolberg AS, Pawlinski R, Key NS, **Yeh JJ**, Mackman N. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. *Blood*. 2012 Jun 119(23):5543-52.
65. Chaika NV, Yu F, Purohit V, Mehla K, Lazenby AJ, DiMaio D, Anderson JM, **Yeh JJ**, Johnson KR, Hollingsworth MA, Singh PK. Differential expression of metabolic genes in tumor and stromal components of primary and metastatic loci in pancreatic adenocarcinoma. *PLoS One*. 2012, Mar;7(3):e32996.
66. Martin TD, Mitin N, Cox AD, **Yeh JJ**, Der CJ. Phosphorylation by protein kinase C alpha regulates RalB small GTPase activation, subcellular localization, and effector utilization. *J Biol Chem*. 2012, Apr 287(18):14827-36.
67. Neel NF, Rossman KL, Martin TD, Hayes TK, **Yeh JJ**, Der CJ. The RalB small GTPase mediates formation of invadopodia through a GTPase-activating protein-independent function of the RalBP1/RLIP76 effector. *Mol Cell Biol*. 2012, Apr; 32(8):1374-86.
68. Jovov B, Araujo-Perez F, Sigel C, Stratford JK, McCoy AN, **Yeh JJ**, Keku T. Differential gene expression between African American and European American colorectal cancer patients. *PLoS One*. 2012, Jan;7(1):e30168.
69. Cook DR, Solski PA, Bultman SJ, Kauselmann G, Schoor M, Kuehn R, Friedman LS, Cowley DO, Van Dyke T, **Yeh JJ**, Johnson L, Der CJ. The Ect2 Rho guanine nucleotide exchange factor is essential for early mouse development and normal cell cytokinesis and migration. *Genes Cancer* 2011, Oct;2(10):932-42.
70. Xu D, Allsop SA, Witherspoon SM, Snider JL, **Yeh JJ**, Fiordalisi JJ, White CD, Williams D, Cox AD, Baines AT. The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells. *Carcinogenesis*. 2011 Apr;32(4):488-95.
71. Martin TD, Samuel JC, Routh ED, Der CJ, **Yeh JJ**. Activation and involvement of ral GTPases in colorectal cancer. *Cancer Res*. 2011 Jan 1;71(1):206-15.
72. Meyers MO, **Yeh JJ**, Deal AM, Byerly FL, Woosley JT, Frank J, Long PK, Amos KD, Ollila DW. Age and breslow depth are associated with a positive sentinel lymph node in patients with cutaneous melanocytic tumors of uncertain malignant potential. *J Am Coll Surg*. 2010 Dec;211(6):744-8.
73. Vigil D, Martin TD, Williams F, **Yeh JJ**, Campbell SL, Der CJ. Aberrant overexpression of the Rg12 Ral small GTPase-specific quinone nucleotide exchange factor promotes pancreatic cancer growth through Ral-dependent and Ral-independent mechanisms. *J Biol Chem*. 2010 Nov 5;285(45):34729-40. Epub 2010 Aug 27.

74. Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA, Marron JS, Routh ED, Caskey LS, Samuel JC, Der CJ, Thorne LB, Calvo BF, Kim HJ, Talamonti MS, Iacobuzio-Donahue CA, Hollingsworth MA, Perou CM, **Yeh JJ**. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. *PLoS Medicine*. 2010 June 13;7(7):e1000307.
75. Goicoechea SM, Bednarski B, Stack C, Cowan DW, Volmar K, Thorne L, Cukierman E, Rustgi AK, Brentnall T, Hwang RF, McCulloch CA, **Yeh JJ**, Bentrem DJ, Hochwald S, Hingorani SR, Kim HJ, Otey CA. Isoform-specific upregulation of palladin in human and murine pancreas tumors. *PLoS One*. 2010 April 26;5(4):e10347.
76. Meyers MO, Russell CP, Ollila DW, **Yeh JJ**, Kim HJ, Calvo BF. Postoperative hypocalcemia after parathyroidectomy for renal hyperparathyroidism in the era of cinacalcet. *American Surgeon* 2009 Sep;75(9):843-7.
77. Kim WY, Perera S, Zhou B, Carretero J, **Yeh JJ**, Heathcote SA, Jackson AL, Nikolinakos P, Ospina B, Naumov G, Brandstetter KA, Weigman VJ, Zaghlul S, Hayes DN, Padera RF, Heymach JV, Kung AL, Sharpless NE, Kaelin WG Jr, Wong KK. HIF2a cooperates with RAS to promote lung tumorigenesis in mice. *Journal of Clinical Investigation*. 2009 Aug;119(8):2160-7.
78. Ollila DW, Ashburn JH, Amos KD, **Yeh JJ**, Frank JS, Deal AM, Long P, Thomas ND, Meyers MO. Metastatic melanoma cells in the sentinel node cannot be ignored. *Journal of the American College of Surgeons*. 2009 May; 208(5):924-9; discussion 929-30.
79. **Yeh JJ**, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ, Sandler RS, Kim HJ, Keku TO, Der CJ. KRAS/BRAF mutation status and ERK 1/2 activation as a biomarker for MEK 1/2 inhibitor therapy in colorectal cancer. *Molecular Cancer Therapeutics*. 2009 Apr; 8(4):834-43.
80. Meyers MO, **Yeh JJ**, Frank J, Long P, Deal AM, Amos KD, Ollila DW. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. *Ann Surg Oncol*. 2009 Apr; 16(4):941-7.
81. Bilimoria KY, Bentrem DJ, Linn JG, Freil A, **Yeh JJ**, Stewart AK, Winchester DP, Ko CY, Talamonti MS, Sturgeon C. Utilization of total thyroidectomy for papillary thyroid cancer in the United States. *Surgery*. 2007 Dec;142(6):906-913. Discussion 913. Epub 2007 Nov 5. Erratum in: *Surgery*. 2008 Feb;143(2):302.
82. **Yeh JJ**, Gonen M, Tomlinson JS, Idrees K, Brennan MF, Fong Y. Impact of blood transfusion on patients undergoing pancreaticoduodenectomy for exocrine tumors of the pancreas. *British Journal of Surgery*. 2007 Apr; 94(4) 466-72.
83. **Yeh JJ**, Shia JR, Hwu WJ, Busam KJ, Paty PB, Guillem JG, Coit DG, Wong WD, Weiser MR. The role of abdominoperineal resection as surgical therapy for anorectal melanoma. *Annals of Surgery*. 2006 Dec; 244(6):1012-17.
84. Bentrem DJ, **Yeh JJ**, Kirin RP, Pastores S, Brennan MF, Fong Y. Predictors of ICU admission and related outcome for patients after pancreaticoduodenectomy. *Journal of Gastrointestinal Surgery*. 2005 Dec; 9(9): 1307-12.
85. Roggin KK, **Yeh JJ**, Ferrone CR, Riedel E, Gerdes H, Klimstra DS, Jaques DP, Brennan MF. Limitations of ampullectomy in the treatment of non-familial ampullary neoplasms. *Annals of Surgical Oncology*. 2005 Dec; 12(12):971-80.
86. **Yeh JJ**, Singer S, Jaques DP, Brennan MF. Effectiveness of palliative procedures for intra-abdominal sarcomas. *Annals of Surgical Oncology*. 2005 Dec; 12(12):1084-9.
87. **Yeh JJ**, Weiser MR, Shia J, Hwu WJ. Response of stage IV anal mucosal melanoma to chemotherapy. *Lancet Oncol*. 2005 Jun;6(6):438-9.
88. Majumder PK*, **Yeh JJ***, George DJ, Febbo PG, Kum J, Xue X, Bikoff R, Ma H, Kantoff PW, Golub TR, Loda M, Sellers WR. Prostate intraepithelial neoplasia induced by prostate

- restricted Akt expression: the MPAKT model. *Proceedings of the National Academy of Sciences*. 2003 Jun 24; 100(13):7841-6. Epub 2003 Jun 10 ***equal contribution**
89. Gimm O, Perren A, Weng LP, Marsh DJ, **Yeh JJ**, Ziebold U, Hinze R, Delbridge L, Lees JA, Mutter GL, Robinson BG, Komminoth P, Dralle H, Eng C. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. *American Journal of Pathology* 2000 Jan; 156(5): 1693-700.
90. **Yeh JJ**, Lunetta KL, van Orsouw NJ, Moore, Jr., FD, Mutter GL, Vijg J, Dahia PLM, and Eng C. Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in thyroid tumours. *Oncogene*. 2000 Apr; 19(16):2060-2066.
91. **Yeh JJ**, Marsh DJ, Zedenius J, Dwight T, Delbridge L, Robinson BG, and Eng C. Fine-structure deletion mapping of 10q22-24 identifies regions of loss of heterozygosity and suggests that sporadic follicular thyroid adenomas and follicular thyroid carcinomas develop along distinct neoplastic pathways. *Genes, Chromosomes & Cancer*. 1999 Dec; 26(4):322-328.

PRESENTATIONS

Local Presentations

1. 04/2022 Precision approaches in pancreatic cancer. *45th Annual UNC Lineberger Scientific Symposium*. **Invited lecturer.**
2. 04/2019 Pancreatic cancer subtypes for precision medicine. *43rd Annual UNC Lineberger Scientific Symposium*. **Invited lecturer.**
3. 05/2018 Deconstructing pancreatic cancer for precision medicine. *Oliver Smithies Investigators Honorary Lectures*. **Invited lecturer.**
4. 01/2017 Deconstructing Pancreatic Cancer. *Department of Pathology Grand Rounds, University of North Carolina, Chapel Hill*. **Invited lecturer.**
5. 10/2016 Deconstructing Pancreatic Cancer. *Center for Gastrointestinal Biology and Diseases, University of North Carolina, Chapel Hill*. **Invited lecturer.**
6. 01/2016 Goings on. *Department of Surgery Grand Rounds, University of North Carolina, Chapel Hill*. **Invited lecturer.**
7. 06/2013 Pancreatic cancer. *Howard Hughes Medical Institute/Med into Grad Seminar Series*. **Invited lecturer.**
8. 11/2012 Mouse models. *Center of Cancer Nanotechnology Excellence*. **Invited lecturer.**
9. 07/2011 Therapeutic targets in pancreatic cancer. *MD PhD Retreat*. **Invited lecturer.**
10. 12/2010 Strategies to identify novel targets for GI cancers. *Department of Surgery Grand Rounds, University of North Carolina, Chapel Hill*. **Invited lecturer.**
11. 09/2010 In search of therapeutic targets. *Genetics and Molecular Biology Scientific Retreat*. **Invited lecturer.**
12. 09/2010 Kinases off the beaten path. *Center for Gastrointestinal and Biology Disease*. **Invited lecturer.**
13. 08/2010 From bench to bedside and back: in search of therapeutic targets. *Board of Visitors, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill*. **Invited lecturer.**
14. 03/2010 Colorectal cancer: a surgical oncology perspective. *Howard Hughes Medical Institute/Med into Grad Seminar Series*. **Invited lecturer.**
15. 08/2009 Surgery, research, and personalized medicine. *Department of Surgery Grand Rounds, University of North Carolina, Chapel Hill*. **Invited lecturer.**
16. 02/2009 From bench to bedside and back: in search of therapeutic targets. *Department of Pharmacology Seminar Series*. **Invited lecturer.**

17. 10/2006 Parathyroid and thyroid disease. *Johnston Medical Society, NC (AHEC)*. **Invited lecturer.**
18. 01/2006 Rational targeting of solid tumors. *Department of Surgery Grand Rounds, University of North Carolina, Chapel Hill*. **Invited lecturer.**

Regional/National/International Presentations

1. 10/2023 Breaking down pancreatic cancer. *MD Anderson Cancer Center Surgical Oncology Grand Rounds*. **Invited lecturer.**
2. 01/2023 Building an effective research toolkit for success as an early career academic HPB surgeon. *AHPBA Webinar*. **Invited lecturer.**
3. 10/2022 My journey: breaking down pancreatic cancer. *University of Rochester Medical Center Grand Rounds, Rochester, NY*. **Invited lecturer.**
4. 09/2022 Precision approaches in pancreatic cancer. *AACR Pancreatic cancer, Boston, MA*. **Invited lecturer.**
5. 09/2022 Breaking down pancreatic cancer. *University of Florida Health Center Oncology Grand Rounds, Gainesville, FL*. **Invited lecturer.**
6. 06/2022 New avenues in pancreatic cancer treatment. Molecular Medicine from Laboratory to Practice. *Panhellenic Conference, Athens, Greece*. Virtual **Keynote lecturer.**
7. 03/2022 Precision approaches in pancreatic cancer. *Society of Surgical of Oncology, Dallas, Texas*. **Invited lecturer.**
8. 01/2022 Molecular subtypes in pancreatic cancer. 11th Annual Medical College of Wisconsin Pancreatic Cancer Symposium. **Invited lecturer.**
9. 08/2021 Pancreatic cancer subtypes and chemotherapy selection. *Americas Hepatobiliary Association*. **Invited lecturer.**
10. 06/2021 Transcriptomic compartments of pancreatic cancer. Sylvester Comprehensive Cancer Center at the *University of Miami Distinguished Lecture Series*. Virtual. **Invited lecturer.**
11. 06/2021 Transcriptomic compartments of pancreatic cancer. *City of Hope Comprehensive Cancer Center Seminar Series, Department of Molecular Diagnostics and Experimental Therapeutics*. Virtual. **Invited lecturer.**
12. 05/2021 PDAC subtyping for the clinic. *University of California Pancreatic Consortium*. Virtual. **Invited lecturer.**
13. 10/2020 Tumor Deconvolution. *University of Cincinnati Cancer Center Symposium on Tumor Microenvironment*. Virtual. **Invited lecturer.**
14. 09/2020 Deconvolving tumors to understand tumor and tumor microenvironment signals. *Association of Chinese Americans in Cancer Research*. Virtual. **Invited lecturer.**
15. 11/2019 Genomic Heterogeneity and Precision Medicine in Pancreatic Cancer. *50th American Pancreatic Association Annual meeting in partnership with the Japan Pancreas Society*. Kauai, HI. **Invited lecturer.**
16. 10/2019 The Use of Genetic Testing - Should All Newly Diagnosed Pancreatic Ductal Adenocarcinoma (PDA) undergo genetic testing? *American College of Surgeons Clinical Congress*. **Invited lecturer**
17. 09/2019 Molecular subtypes – bench to bedside. *AACR Pancreatic cancer: advances in science and clinical care*. Boston, MA. **Invited lecturer.**
18. 04/2019 Deconstructing tumors for precision medicine. *DSR Sarma Lectureship in Oncologic Pathology*. *University of Toronto*. **Invited lecturer.**
19. 03/2019 Genomics and precision medicine. *Americas Hepato-Pancreato-Biliary Association*. **Invited lecturer.**

20. 11/2018 Molecular subtypes for precision medicine in pancreatic cancer. *Peter J. Mozden, MD Lecture. Peter J. Mozden, MD Visiting Professorship in Surgical Oncology. Boston Medical Center. Invited lecturer.*
21. 11/2018 Changing paradigms in pancreatic cancer. *Boston Medical Center Grand Rounds. Peter J. Mozden, MD Visiting Professorship in Surgical Oncology. Invited lecturer.*
22. 09/2018 Deconstructing pancreatic cancer for precision medicine. *North Dakota State University, Department of Pharmaceutical Sciences and COBRE. Invited lecturer.*
23. 03/2018 Molecular subtypes predict response to chemotherapy in pancreatic cancer. *Society of Surgical Oncology. Plenary.*
24. 10/2017 Iontophoresis for delivery of chemotherapy to locally advanced pancreatic cancer. *American College of Surgeons Clinical Congress. Invited lecturer.*
25. 10/2017 Understanding molecular subtypes in pancreatic cancer. *2017 Gigi Shaw Arledge Conference on Pancreatic Disease. Invited lecturer.*
26. 10/2017 Surgical Oncology Session. *American College of Surgeons Clinical Congress. Moderator.*
27. 04/2017 Howard Hughes Medical Institute Medical Fellows Session, *Chicago, IL. Panelist.*
28. 02/2017 Deconstructing pancreatic cancer to understand tumor specific signals. *Third Annual Feeney Distinguished Lecturer in HPB Surgical Oncology, University of Toronto. Invited lecturer.*
29. 11/2016 Deconstructing pancreatic cancer to understand tumor specific signals. *Memorial Sloan-Kettering Cancer Center Center for Pancreatic Cancer Research. Invited lecturer.*
30. 05/2016 Deconstructing Pancreatic Cancer. *AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care. Invited lecturer.*
31. 04/2016 Serendipity, Integration, and Synergy. *The Inaugural Women in Surgery Lectureship, University of Alabama School of Medicine Department of Surgery. Keynote lecturer.*
32. 02/2016 Identifying subtypes in pancreatic cancer. *Mayo Clinic SPORE in Pancreatic Cancer Investigators Conference. Invited lecturer.*
33. 10/2015 Surgical Oncology Session. *American College of Surgeons Clinical Congress. Moderator.*
34. 12/2014 Pancreatic cancer, a clinician's perspective. *Annual NCI Alliance for Nanotechnology in Cancer Investigators' Meeting. Invited lecturer.*
35. 10/2014 Translational research in pancreatic cancer. *Surgical Biology Club. Invited lecturer.*
36. 10/2014 The road to tumor subtypes in pancreatic cancer. *University of Wisconsin Department of Surgery Grand Rounds. Invited lecturer.*
37. 09/2014 Management of patients with a new diagnosis of well-differentiated thyroid cancer. *Masters Course in Endocrine Surgery. Invited lecturer.*
38. 03/2014 Circulating tumor cells in pancreatic cancer. *Masters Course in Endocrine Surgery. Invited lecturer.*
39. 10/2013 Kinome landscape of pancreatic cancer. *Lustgarten Foundation Scientific Meeting. Invited lecturer.*
40. 10/2012 Developing molecular markers for pancreatic cancer. *3rd Annual Meeting of the Society for Translational Oncology. Invited lecturer.*

41. 10/2012 Triptolide and sorafenib combination therapy in hepatocellular carcinoma results in superior cell death in vitro and prolonged survival in vivo. Targeted Therapies Session. *American College of Surgeons Clinical Congress*. **Discussant.**
42. 11/2010 Ral pathway in pancreatic cancer. *American Pancreatic Association*. **Invited lecturer.**
43. 03/2010 Targets along the Ras pathway. *Society of Surgical Oncology*. **Invited lecturer.**
44. 06/2009 Targeting aurora kinase in GI cancers. *Cancer and Leukemia Group B*. **Invited lecturer.**
45. 03/2009 A molecular signature of clinical risk in patients with metastatic colorectal cancer. **Plenary presentation**, *Society of Surgical of Oncology*.
46. 03/2008 Prognostic signature for pancreatic ductal adenocarcinoma. **Plenary presentation**, *Society of Surgical of Oncology*
47. 03/2005 Effectiveness of palliative procedures for intra-abdominal sarcomas. **Oral presentation**. *Society of Surgical Oncology*.
48. 2005 Extent of surgical resection and disease outcome: 20-year analysis of changing treatment strategies for anorectal melanoma. **Oral presentation**. *American Society of Colorectal Surgeons*.
49. 06/2005 Significance of necrosis and gene expression profiling in myxoid-round cell liposarcoma of the extremity. **Poster Discussion** *American Society of Clinical Oncology*.
50. 2001 Mitochondrial DNA alterations and thyroid tumors. *European Thyroid Cancer Research Network*. **Invited lecturer.**
51. 2000 AKT and prostate tumorigenesis. **Oral presentation**. *New England Cancer Society*.
52. 2000 AKT and prostate tumorigenesis. **Oral presentation**. *Sixth Annual Surgical Research Symposium at the New England Medical Center Hospital*.
53. 1999 Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in malignant and benign thyroid tumors, **Oral presentation**. *American Society of Human Genetics*.
54. 1999 Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in malignant and benign thyroid tumors, **Oral presentation**. *New England Cancer Society*.
55. 1999 Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in malignant and benign thyroid tumors, **Oral presentation**. *Fifth Annual Surgical Research Symposium at the New England Medical Center Hospital, Boston, MA*

GRANT SUPPORT:

ACTIVE

P50CA257911-01A1	(Yeh)	09/16/2022 – 08/31/2027
National Cancer Institute	Role: PI	2.4Cal (20.00%)
Selective Targeting of Pancreatic Cancer SPORE		

U01CA274298	(MPI Yeh (contact), Tsai, Rashid)	09/01/2022 – 08/31/2027
National Cancer Institute	Role: PI	1.2Cal (10.00%)
Integrating tumor and stroma to understand and predict treatment response		

NA Lustgarten Foundation	(MPI Yeh (contact), Maduekwe) Role: PI	01/01/2023 – 12/31/2026	
PROmoting CLinicAL Trial EngageMent for Pancreatic Cancer App Study (PROCLAIM Study)			
U24CA264027 National Cancer Institute	(MPI Raphael (contact), Yeh) Role: PI	9/22/21-8/31/26	1.2Cal (10.00%)
Pathway, Network and Spatiotemporal Integration of Cancer Genomics Data			
T32-CA244125 National Cancer Institute	(MPI Yeh (contact), Kim) Role: PI	9/1/19-8/31/24 573,747.00	N/A
UNC Integrated Translational Oncology Training Program (UNC-iTOP)			
T32-GM122741-01A1 NIGMS	(MPI Wolberg (contact), Yeh) Role: PI	7/1/18-6/30/23 173,017.00	N/A
Enhancement Training for the Next Generation of Translational Ph.D. Scientists			
R01CA190717-01 National Cancer Institute	(Bogdanov)/UCincinnati subcontract Role: Co-Investigator	7/1/18-6/30/23 290,978.00	0.60 Cal (5.00%)
Alternatively spliced tissue factor and pathobiology in pancreatic cancer			
R01CA224763-01A1 National Cancer Institute	(MPI Allbritton (contact), Lawrence) Role: Co-Investigator	4/1/18-3/31/24 488,977.00	0.5 Cal (4.00%)
Profiling signaling activity and gene expression in single, pancreatic adenocarcinoma cells using CE-RNA-Seq			
P30 CA016086 National Cancer Institute	(PI Earp) Role: Program Leader, co-Director Cancer Research Career Enhancement Core	12/1/15-11/30/25 7,252,540.00	1.8 Cal (15.00%)
Cancer Center Core Support Grant			
Not Assigned University of Cincinnati Falk Catalyst Award	(PI Bogdanov) Role: Co-Investigator	4/1/22-3/31/24	0.24 Cal (2.00%)
Preclinical Development of a First-In-Class Humanized Antibody Targeting Alternatively Spliced Tissue Factor			
R37 CA230786-01A1 National Cancer Institute	(PI Pylayeva-Gupta) Role: Co-Investigator	4/1/19-3/31/24	0.24 Cal (2.00%)
Function of IL35+ B cells in pancreatic cancer			
R01 CA263897 National Cancer Institute	(PI Vivero-Escoto) Role: Co-Investigator	8/1/22-7/31/27	0.6 Cal (5.00%)

Stimuli-responsive mucin1-specific nanoparticles for efficacious combinatorial chemotherapy of pancreatic ductal adenocarcinoma

PENDING

R01-CA288145 (MPI Yeh (contact), Johnson) 1/1/24-12/31/2029 1.2 Cal (10.00%)
National Cancer Institute Role:PI
Targeted approaches for basal subtype pancreatic cancer

COMPLETED

R01-CA199064 (MPI Yeh (contact), Tsai) 9/1/16-7/31/26 1.2 Cal (10.00%)
National Cancer Institute Role: PI 600,010.00
Tumor subtypes and therapy response in pancreatic cancer

U24-CA211000 (MPI Raphael (contact), Yeh) 10/1/16-9/30/21 1.2 Cal (10.00%)
National Cancer Institute Role: PI 376,097.00
Pathway and Network Integration of Cancer Genomics and Clinical Data

R01-CA199064 (MPI Yeh (contact), Johnson, Graves) 9/1/16-7/31/21 2.4 Cal (11.00%)
National Cancer Institute Role: PI 600,010.00
Tumor subtypes and therapy response in pancreatic cancer

R01-CA199064 03S1 (Yeh) 9/1/16-7/31/21 0.6 Cal (3.3%)
National Cancer Institute Role: PI 171,400.00
Purity Independent Single Sample Classifier for Pancreatic Cancer

5-UL-1TR002489-04 (Buse) 03/30/2018- 0.60 Cal (5.00%)
National Center for Advancing Role: Review committee 02/28/2023
Translational Sciences
North Carolina Translational and Clinical Science Institute (NC TraCS)

2-P01-CA142538-06 (Kosorok) 4/1/10-3/31/20 0.5 Cal (4.00%)
National Cancer Institute Role: Co-Investigator 375,446.00
Statistical Methods for Cancer Clinical Trials: Project 5 - Methods for Discovery and Analysis of Dynamic Treatment Regimes

Research Acceleration Network-2 (MPI Linehan, Wolpin) 7/1/16-6/30/20 0.6 Cal (5.00%)
AACR Role: Co-Investigator
Targeting macrophages to improve chemotherapy in metastatic pancreas cancer

1-U01-CA151455-05 (MPI Lin, Yeh) 12/1/10-7/31/16 7.50%
National Inst. of Health Role: PI 400,000.00
Nanoscale Metal-organic Frameworks for Imaging and Therapy of Pancreatic Cancer

5-R01-CA140424-05 (Yeh) 4/8/10 -1/31/16 25.00%
National Cancer Institute Role: PI 195,237.00
Targeting Ras-Ral GEF-Ral Effector Signaling for Pancreatic Cancer Treatment

5-R01-CA042978-28 (Der) 8/1/10 -1/31/16 5.00%

National Cancer Institute	Role: Co-Investigator	234,767.00	
Biological Activity of Ras Oncogenes			
1-R01-CA139599-01	(Allbritton)	4/1/09-3/31/14	10.00%
National Cancer Institute	Role: Co-Investigator	347,832.00	
Multiplexed Measurement of Kinase Activity in Single Cancer Cells			
1-P50-CA106991-05	(Tepper)	8/1/04-7/31/10	20.00%
National Cancer Institute	Role: Project Co-Leader		
SPORE in Gastrointestinal Cancer: Project 4 – Targeting Ras Effector Signaling for Colorectal Cancer Treatment			
HHSN261201300071C	(Hupert)	12/1/13 -11/30/15	8.30%
National Cancer Institute	Role: Co-Investigator	248,892.00	
Low-Cost Microfluidic System for Detection of CTCs			
Not Assigned	(Der, Co-PI Yeh)	10/01/11-9/30/13	1.00%
GlaxoSmithKline, Inc	Role: PI	235,617.00	
Analyses of the Anti-tumor Activity of a MEK1/2-selective Protein Kinase Inhibitor in Mouse Models of Pancreatic Cancer			
Not Assigned	(MPI Walker, Ligler, Yeh)	5/1/14-4/30/15	N/A
NC TraCS	Role: PI		
Development of a Point-of-Surgery Parathyroid Hormone Monitor			
Not Assigned	(Der, Co-PI Yeh)	2/1/12-1/31/15	10.00%
Lustgarten Foundation		291,290.00	
Mechanisms of ERK inhibition resistance and identification of K-Ras effector signaling components essential for ERK-dependent pancreatic cancer growth			
Not Assigned	(Yeh)	2/1/12-1/31/13	
NCTraCS	Role: PI		
Isolating Circulating Tumor Cells in Metastatic Melanoma with Microfluidics			
Not Assigned	(Yeh)	7/1/09-6/30/12	15.00%
American Surgical Association Foundation	Role: PI	75,000.00	
Targeting the Ras-RalGEF-Ral Pathway in Pancreatic Cancer			
SKF-08-113	(Yeh)	7/1/08-6/30/11	15.00%
		86,957.00	
Identification and Validation of Novel Targets for the Treatment of Pancreatic Cancer Using a Prognostic Gene Signature			
Not Assigned	(Yeh)	7/1/08-6/30/10	5.00%
American College of Surgeons	Role: PI	40,000.00	
Identification and Validation of Targets Associated with Prognosis in Pancreatic Cancer			

PATENTS

Interventional drug delivery system and associated methods
U.S. Application No. 10,695,562

In vitro capture and analysis of circulating tumor cells.
U.S. Application No. 9,952,212

Methods and compositions for prognostic subtyping of pancreatic cancer.
U.S. Application No. 11,053,550

De novo compartment deconvolution and weight estimation of tumor tissue samples (DECODER)
U.S. Application No. 17,336,600

Purity independent subtyping of tumors (PurIST)
U.S. Application No. 17,601,002

A methylation-based classifier for PDAC
U.S. Application Provisional Filed

Kinase inhibitors for pancreatic cancer
U.S. Application Provisional Filed

PROFESSIONAL SERVICES:

National/International Committees:

2023-	Seena Magowitz Foundation Pancreatic Cancer Medical Advisory Board
2023-	Pancreatic Cancer Action Network Scientific and Medical Advisory Board
2022-	Americas Hepato-Pancreatico-Biliary Association Thought Leader Research Focus Group
2023- 2021-2024	American College of Surgeons National Surgeon Scientist Program Committee Cancer and Endocrine Subcommittee, American Surgical Association Program Committee
2021-2023	Conference Co-chair for the AACR Special Conference on Pancreatic Cancer
2021-	Lustgarten Foundation Scientific Advisory Board
2020-2023	Committee for the Owen H. Wangenstein Scientific Forum (Surgical Oncology, leader), American College of Surgeons
2020-	Duke University Medical Center Surgical Oncology T32 Training Program, External Advisory Board
2019-2020	EORTC-NCI-AACR Symposium Scientific Program Committee
2019-2023	Stand Up to Cancer (SU2C)-Lustgarten Foundation Pancreatic Cancer Dream Team Review Committee
2017-2019	American College of Surgeons Surgical Forum Abstract Review Committee
2017	Senior Appointment Committee Cancer Research UK, Manchester Institute
2017-2018	American Board of Surgery Certifying Exam Broad HPB Subcommittee
2013-2017	TCGA PAAD Workgroup
2013-2014	Stand Up to Cancer- Lustgarten Foundation Joint Scientific Advisory Committee (JSAC)

2009-2012 Cancer and Leukemia Group B Gastrointestinal Cancer Surgery and Correlative Sciences Committees
2009 – 2010 NCI Colon Task Force, Junior Investigator

Institutional Committees:

2022- present Preclinical Studies Core Advisory Committee
2021 Working Forward Committee
2020-present Office of Medical Student Research Advisory Committee
2020 School of Medicine Clinical Research Review Committee
2019 School of Medicine Master Plan Steering Committee
2019-present Medical Scientist Training Program Advisory Board/Admissions Committee
2019 School of Medicine Program for Precision Medicine in Healthcare Biobanking Working Group
2019 School of Medicine Translational Research Building Scientific Advisory Committee
2019 School of Medicine Translational Research Building Enrichment, Surgery, Imaging Specials Program Committee
2018 School of Medicine Office of Physician Scientist Training and Education Planning Working Group
2018-2019 Lineberger Comprehensive Cancer Center Strategic Planning Committee Out of the Box Working Group
2017-2018 Carolina Medical Student Research Program Study Section (T35)
2016 Five-year Review Committee for Dr. Nancy Allbritton, Chair of BME
2015 – Present Lineberger Comprehensive Cancer Center Program Planning Committee
2015 – Present Lineberger Comprehensive Cancer Center Faculty Search Committee
2015 – Present Shared Resources Committee
2015 – 2022 Animal Histopathology Core Advisory Committee
2011 – 2022 Animal Studies Core Advisory Committee
2007 – 2016 UNC Data Warehouse Operations Committee
2009 – 2014 Translational Pathology Laboratory Advisory Board
2008 – 2014 Teaching Physicians Oversight Committee
2010, 2011 Carolina Medical Student Research Program Study Section (T35)

Grant Reviews:

2020-2025 NIH NCI Molecular Cancer Diagnosis and Classification (MCDC) permanent member
2021-2023 Lustgarten Foundation-AACR Pancreatic Cancer Research Grants Scientific Review Committee
2017-2022 Cancer Prevention and Research Institute of Texas (CPRIT) Clinical Translational Research Panel
12/2020 Lustgarten Foundation Therapeutics Research Program Review Panel
06/2019 NIH NCI Cancer Biomarkers Study Section (CBSS)
03/2019 NIH NCI Molecular Oncology Study Section (MONC)
02/2019 Cancer Research UK Programme Foundation Award
10/2018 NIH NCI Cancer Biomarkers Study Section (CBSS)
7/2018 NIH NCI U01 ZCA1-RPRB-J-O1 Biological Comparisons in Patient-Derived Models of Cancer
6/2018 NIH NCI Developmental Therapeutics (DT) Study Section

5/2018-present Cancer Prevention and Research Institute of Texas Peer Review Meeting
4/2018 Pancreatic Cancer Action Network Scientific Review Committee, 2018
Translational Research Grant
2/2018 NIH NCI U01 ZCA1 SRB-P (M1) Biological Comparisons in Patient-Derived
Models of Cancer
1/2018 Congressionally Directed Medical Research Programs Uniformed Services
University
2017 Washington University Pancreatic Cancer SPORE Developmental Research
Program
10/2017 NIH NCI Developmental Therapeutics (DT) Study Section
9/2017 NIH NCI ZCA1 SRB-C (J2) Emerging Questions in Systems Biology
10/2017 NIH NCI U01 ZCA1 SRB-P (O2) Biological Comparisons in Patient-Derived
Models of Cancer
7/2017 Cancer Prevention and Research Institute of Texas Peer Review Meeting
5/2017 NIH NCI U01 ZCA1 SRB-J (M1) Biological Comparisons in Patient-Derived
Models of Cancer
2017 AACR Pancreatic Cancer Action Network Translational Research Grant
2/2016 NIH NCI R03 & R21 Omnibus ZCA1 SRB-C (M1) S
2014 NIH NCI R03 & R21 Omnibus ZCA1 SRLB-C (M1), Cancer Biology-2
2014 NIH NCI R03 & R21 Omnibus ZCA1 SLB-C (J1), SEP-2
2014 NIH ZRG1 BST-F (55) R Bioengineering Research Partnership
2013 NIH NCI Provocative Questions: Cancer Therapy and Outcomes
2010 Ad Hoc Member, NIH NCI SPORE Study Section
2010 Ad Hoc Member, NIH NCI Tumor Progression Metastasis (TPM) Study Section

Manuscript Reviews:

Ad Hoc Reviewer, Annals of Surgery
Ad Hoc Reviewer, Annals of Surgical Oncology
Ad Hoc Reviewer, British Journal of Surgery
Ad Hoc Reviewer, Cell
Ad Hoc Reviewer, Cancer Cell
Ad Hoc Reviewer, Cancer Discovery
Ad Hoc Reviewer, Cancer Research
Ad Hoc Reviewer, Endocrine-Related Cancer
Ad Hoc Reviewer, Gastroenterology
Ad Hoc Reviewer, Journal of Clinical Investigation
Ad Hoc Reviewer, Journal of Clinical Oncology
Ad Hoc Reviewer, Journal of Surgical Oncology
Ad Hoc Reviewer, Nature Communications
Ad Hoc Reviewer, PLoS One
Ad Hoc Reviewer, Science Signaling

Editorial Board:

Section editor, Journal of Surgical Oncology
Section editor, Surgical Oncology, Insight

Other Boards:

Member, Board of Directors, Focal Medical, Inc (co-founder)

PROFESSIONAL SOCIETIES

2017	American Surgical Association
2015	American Association of Endocrine Surgeons
2015	American Society for Clinical Investigation
2013	Society of Clinical Surgery
2013	Surgical Biology Club
2012	Society of University Surgeons
2008-	Association of Academic Surgeons
2006-2011	Cancer and Leukemia Group B, Member
2006-	American College of Surgeons, Fellow
2006-	American Association for Cancer Research
2005-	American Society of Clinical Oncology
2004-	Society of Surgical Oncology
2002	Alpha Omega Alpha Medical Honor Society
2000	Sigma Xi Scientific Honor Society

TEACHING RECORD

Lectures (Graduate Student)

2023	PATH 725, Pancreatic Cancer (1 lecture)
2022	PATH 725, Pancreatic Cancer (1 lecture)
2021	PATH 725, Pancreatic Cancer (1 lecture)
2020	PATH 725, Pancreatic Cancer (1 lecture)
2019	PATH 725, Pancreatic Cancer (1 lecture)
2018	PATH 725, Pancreatic Cancer (1 lecture)
2015	PHCO 730, Target based Anti-Cancer Drug Discovery (1 lecture)
2014	BIOC/MCRO/PHCO/PHYI 643, Translational research in pancreatic cancer (1 lecture)
2013	PHCO 730, Target based Anti-Cancer Drug Discovery (1 lecture)
2011	PHCO 730, Target based Anti-Cancer Drug Discovery (1 lecture)
2009	PHCO 730, Target based Anti-Cancer Drug Discovery (1 lecture)

Tutorials (Medical Student)

2019	Medical Scientist Training Program Longitudinal Clinical Rotation Preceptor
2018	Medical Scientist Training Program Longitudinal Clinical Rotation Preceptor
1/2013	Surgery Rotation Longitudinal Tutorial Preceptor

Lectures (Residents)

2023	Pathogenesis and Management of Thyroid Cancer (Junior/Senior Residents)
2022	Pathogenesis and Management of Thyroid Cancer (Junior/Senior Residents)
12/2018	Pathogenesis and Management of Adrenal Masses (Junior/Senior Residents)
12/2017	Pathogenesis and Management of Thyroid Cancer (Junior Residents)
4/2015	Pathogenesis and Management of Soft Tissue Sarcoma (Junior Residents)
4/2015	Pathogenesis and Management of Soft Tissue Sarcoma (Senior Residents)
3/2015	Pathogenesis and Management of Thyroid Cancer (Junior Residents)
3/2015	Pathogenesis and Management of Thyroid Cancer (Senior Residents)
6/2013	Pathogenesis and Management of Thyroid Cancer (Junior Residents)
6/2013	Pathogenesis and Management of Thyroid Cancer (Senior Residents)
7/2013	Pathogenesis and Management of Soft Tissue Sarcoma (Junior Residents)

7/2013 Pathogenesis and Management of Soft Tissue Sarcoma (Senior Residents)

Lectures (Fellows)

2018-2023 Translational Research
 10/2017 Biology and Management of GIST
 2/2017 Management of Soft Tissue Sarcoma and Metastases
 2/2015 Management of Soft Tissue Sarcoma and Metastases
 5/2014 Biology and Management of GIST
 3/2014 Biology and Management of Adrenal Masses
 3/2013 Management of Soft Tissue Sarcoma and Metastases
 2/2013 Cancer Biology
 5/2012 Biology and Management of GIST
 3/2012 Biology and Management of Adrenal Masses
 2/2011 Biology and Management of Islet Cell Tumors

Graduate Thesis Committees – Alphabetical order:

Marybeth Anderson	UNC Genetics (Yeh)
Whitney Bell	UNC Cell Biology and Physiology (Pylayeva-Gupta)
James Byrne	UNC Chemistry (DeSimone, Yeh)
Yogitha Chareddy	UNC Genetics and Molecular Biology (Pecot)
John Nathaniel Diehl	UNC Pharmacology (Der)
Hannah Hwangbo	UNC Computational Biology (Palmer)
Matt Lipner	UNC Pharmacology (Yeh)
Ian McCabe	UNC Cell Biology and Physiology (Yeh)
Denis Okumu	UNC Pharmacology (Graves)
Ryan Phillips	UNC Chemistry (Allbritton, Lawrence)
Jeran Stratford	UNC Pharmacology (Der, Yeh)
Jason Streeter	UNC/NC State Biomedical Engineering (Dayton)
Yi Xu	UNC Pharmacology (Yeh)
Sandy Zarmer	UNC Pharmacology (Yeh)

Graduate Student Co-Mentor:

<i>Period</i>	<i>Name</i>	<i>Program</i>
2010-2014	James Byrne	UNC Chemistry (J. DeSimone)
2011	Adam Friedman	UNC HHMI Med into Grad (R. Liu)
2009	Lauren Parker	UNC HHMI Med into Grad (A. Cox)

Graduate Student Training:

<i>Period</i>	<i>Name</i>	<i>Dissertation Project</i>
2021 – present	Mariaelena Nabors	Subtype regulation in PDAC
2021 – present	Ian McCabe	Signaling in basal subtype PDAC
2020 – present	Maddy Jenner	Drug sensitivity in tumor and tumor microenvironment
2018 – present	Sandra Zarmer	Identification of vulnerabilities in basal subtype pancreatic cancer
2017 – present	Yi Xu	Determining subtype specific therapies
2014 - 2019	Matthew Lipner	Role of JNK in FOLFOX resistance
2012 - 2014	Lindsay Almquist	Characterization of circulating tumor cells in pancreatic cancer mouse models

2012 –2016	Marybeth Anderson	miRNA regulation of hexokinase 2
2012 – 2014	Rebecca Werlau	Circulating tumors cells in pancreatic cancer
2013 – 2015	Meagan Eldridge	Genomic predictors of FOLFIRINOX response in pancreatic cancer.
2010 – 2014	Jeran Stratford	Aberrant gene expression: diagnostic markers and therapeutic targets for pancreatic cancer

Medical Student Committees and Presentations

6/2014	Carolina Medical Student Research Program Young Investigator Luncheon, panel member	
6/2013	Carolina Medical Student Research Program Young Investigator Luncheon, panel member	
6/2012	Carolina Medical Student Research Program Young Investigator Luncheon, panel member	
6/2011	Carolina Medical Student Research Program Young Investigator Luncheon, panel member	
3/2011	Carolina Medical Student Research Program, Study Section Member	
6/2010	Carolina Medical Student Research Program Young Investigator Luncheon, panel member	
3/2010	Carolina Medical Student Research Program, Study Section Member	
6/2009	Carolina Medical Student Research Program Young Investigator Luncheon, panel member	

Medical Student Research Training:

2022	Michala Patterson	UNC School of Medicine Carolina Medical Student Research Program
2021	Hanna Thel	UNC School of Medicine Carolina Medical Student Research Program
2021	Anika Agarwal	UNC School of Medicine Carolina Medical Student Research Program
2013	Kimmy Vuong	UNC School of Medicine Carolina Medical Student Research Program
2012	Bobby Torphy	UNC School of Medicine Carolina Medical Student Research Program
2011	Ryan Little	UNC School of Medicine Carolina Medical Student Research Program
2009	Robert Eil	UNC School of Medicine
2008	Elizabeth Routh	Wake Forest School of Medicine

Undergraduate Research Training:

Summer 2023	Monique Armelle Dacanay	UNC-NCCU Partners Program
Summer 2019	Nadia McBean	UNC Carolina Summer Fellowship Program
Summer 2019	Kodi Harris	UNC Carolina Summer Fellowship Program
2018-2019	Selina Zhang	UNC
1/2015-4/2017	Lucas Nielsen	UNC Honors Thesis
8/2015-2018	Ashley Morrison	UNC
Summer 2017	Conrad Fletcher	UNC Summer Undergraduate Research Experience (SURE-REU) Program in Molecular Biosciences

6/2015-2017 Charles Klose UNC
Summer 2015 Joy Gullo UNC Summer of Learning and Research (SOLAR)
Program

Postdoctoral Training (Residents):

<i>Training Period</i>	<i>Name</i>	<i>Current Position</i>
2022-	Hannah Trembath	in training
2020 -	Joseph Kearney, MD	in training
2012 - 2014	Christopher Tignanelli, MD	Assistant Professor, University of Minnesota
2011 - 2014	Raheel Jajja, MD	General Surgery Resident, Emory University
2007 – 2008	Jonathan C. Samuel, MD	General Surgeon, Private Practice

Postdoctoral Training (Clinical Fellows):

<i>Training Period</i>	<i>Name</i>	<i>Current Position</i>
2010-2012	Rachel Aufforth, MD	Allina Health, St. Paul, Minnesota
2011-2012	Justin Baker, MD	Allina Health, St. Paul, Minnesota

Postdoctoral Training:

<i>Training Period</i>	<i>Name</i>	<i>Current Position</i>
2021 - 2023	Deborah Weighill, PhD	Senior Scientist, UCB
2020 - 2021	Vincent Perez, PhD	Senior Scientist, Tempus Labs
2017 - 2018	Kyla Collins, PhD	Eli Lilly, Research Scientist
2017 - 2020	Laura Peng, PhD	Research Assistant Professor, UNC Pharmacology
2016 - 2019	Yun Jong Park, PhD	FDA, Research Fellow
2013 - 2016	Raoud Marayati, MD	University of Alabama, Department of Surgery and PhD candidate
2013 - 2016	Elizabeth Flate, PhD	Medical Writer
2011 - 2016	Richard Moffitt, PhD	Assistant Professor tenure track, SUNY Stonybrook
2012 - 2014	Christopher Tignanelli, MD	Assistant Professor tenure track, Univ of Minnesota
2011 - 2012	Yangmei Deng, PhD	Nurse, University of North Carolina at Chapel Hill
2009 - 2012	Yasser Heakal, PhD	Associate Professor (tenured), D'Youville College School of Pharmacy
2009 - 2011	Xianxi Wang, PhD	Research Specialist, University of North Carolina at Chapel Hill
2009 - 2010	Min Zhong, PhD	Lecturer, Auburn University
2009	Patricia Solski, PhD	Research Specialist, Boston University
2008	James Madigan, PhD	Staff Scientist, NIH

Medical student awards and presentations

Awards (medical student)

5/2014	Robert Torphy, George F. Sheldon Surgical Research Award
2014	James Byrne, NC TraCs 2K grant
2014	Marybeth Anderson, 2nd Place, Lineberger Cancer Center Trainee Research Competition, University of North Carolina – Chapel Hill NC

- 2014 Marybeth Anderson, Best Poster Presentation, Center for Gastroenterology Biology and Disease Research Competition, University of North Carolina – Chapel Hill NC
- 2013 Robert Torphy, Scott Neil Schwirck Research Fellowship
- 6/2013 Kimmy Vuong, NIH Short-Term Institutional Research Training Grant (T35) Carolina Medical Student Research Program
- 6/2012 Robert Torphy, NIH Short-Term Institutional Research Training Grant (T35) Carolina Medical Student Research Program
- 6/2011 Ryan Little, NIH Short-Term Institutional Research Training Grant (T35) Carolina Medical Student Research Program

Local Presentations (medical student)

1. 2/2015 Anderson M, **Yeh JJ**. HK2 is Necessary for Tumor Growth and Metastasis in Pancreatic Cancer (Poster) John B. Graham Student Research Day. University of North Carolina School of Medicine, Chapel Hill, NC
2. 9/2014 Anderson M, **Yeh JJ**. HK2 is Necessary for Tumor Growth and Metastasis in Pancreatic Cancer (Poster) Lineberger Comprehensive Cancer Center Annual Scientific Symposium. University of North Carolina School of Medicine, Chapel Hill, NC
3. 8/2014 Anderson M, **Yeh JJ**. HK2 is Necessary for Tumor Growth and Metastasis in Pancreatic Cancer (Poster) Center for Gastrointestinal Biology and Disease Research Competition University of North Carolina, Chapel Hill, NC
4. 5/2014 Torphy RJ, Tigananelli CJ, Kamande JW, Moffitt RA, Herrera Loeza SG, Soper SA, **Yeh JJ**. Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma. (Oral presentation) Womack Surgical Society Meeting. Chapel Hill, NC
5. 11/2013 Anderson, M, **Yeh JJ**. MiRNA – mRNA Regulatory Networks in Pancreatic Cancer (Oral Presentation) Center for Gastrointestinal Biology and Disease Research Competition University of North Carolina, Chapel Hill, NC
6. 10/2013 Anderson, M, **Yeh JJ**. MicroRNAs, Metastasis, and Me. (Oral presentation) Tobacco Road Medical Research Symposium, University of North Carolina Chapel Hill and Duke University
7. 1/2013 Torphy RJ, Tigananelli CJ, Kamande JW, Moffitt RA, Herrera Loeza SG, Soper SA, **Yeh JJ**. Circulating tumor cells as an early biomarker of response to treatment in patient-derived xenograft models of pancreatic cancer. (Oral presentation) John B. Graham Student Research Day. University of North Carolina School of Medicine, Chapel Hill, NC
8. 1/2013 Lipner MB, **Yeh JJ**. miRNA regulated genes in pancreatic cancer. John B. Graham Student Research Day Presentation. (Poster) John B. Graham Student Research Day. University of North Carolina School of Medicine, Chapel Hill, NC
9. 11/2012 Anderson, M, **Yeh JJ**. MiRNA – mRNA Regulatory Networks in Pancreatic Cancer (Poster) Center for Gastrointestinal Biology and Disease Research Competition University of North Carolina, Chapel Hill, NC

National Presentations (medical student)

1. 5/2015 Torphy RJ, Cader SC, **Yeh JJ**. Quantification of tumor stroma as a biomarker in pancreatic adenocarcinoma. (Poster Discussion) American Society of Clinical Oncology. Chicago, IL
2. 3/2015 Torphy RJ, Cader SC, **Yeh JJ**. Desmoplastic Stroma Differences in Metastatic Pancreatic Cancer. (Oral presentation) Society of Surgical Oncology. Houston, TX
3. 5/2014 Byrne JD, Jajja MR, Schorzman AN, Keeler AW, O'Neill A, Luft JC, Zamboni WC, DeSimone JM, **Yeh JJ**. Local iontophoretic delivery of FOLFIRINOX minimizes systemic

- toxicity for the treatment of pancreatic cancer. (Poster) AACR Pancreatic Cancer: Innovations in Research and Treatment, New Orleans, LA
4. 2/2014 Torphy RJ, **Yeh JJ** . Development of negative selection method for isolation of circulating tumor cells in preclinical models. (Oral presentation) Academic Surgical Congress. San Diego, CA
 5. 10/2013 Torphy RJ, Tigananelli CJ, Kamande JW, Moffitt RA, Herrera Loeza SG, Soper SA, **Yeh JJ**. Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma. (Oral presentation) American College of Surgeons Clinical Congress, Washington, DC
 6. 2/2013 Torphy RJ, Tigananelli CJ, Kamande JW, Moffitt RA, Herrera Loeza SG, Soper SA, **Yeh JJ**. Isolation of circulating tumor cells from patient derived xenograft mouse models of pancreatic cancer. (Oral presentation) Academic Surgical Congress. New Orleans, LA

Resident awards and presentations

Awards (resident)

- | | |
|-----------|--|
| 2021 | Joseph Kearney, Steve Sotsky Award, AHPBA 2021 |
| 2017 | Jonathan Black, Southeastern Surgical Congress Best Paper Award |
| 2016 | Mary Kate Bryant, UNC Hospital Sheldon Research Day Best Poster Award |
| 2015 | Christopher Tiganelli, Herbert J. Proctor Award for Excellence in Surgical Research, University of North Carolina |
| 8/2014 | Christopher Tiganelli, John William Pope Clinical Fellow Award, University of North Carolina |
| 10/2013 | Christopher Tiganelli, Runner-up, Best Oral Presentation 38th Annual Lineberger Postdoc – Faculty Research Day, University of North Carolina |
| 11/2013 | Christopher Tiganelli, Young Investigator Travel Award, American Pancreatic Association |
| 2013 | Christopher Tiganelli, Womack Surgical Research and Outreach Grant (\$10,000) |
| 2012-2014 | Christopher Tiganelli, Surgical Oncology Research Training Program (NIH T32) |
| 2012-2014 | Christopher Tiganelli, American College of Surgeons: Resident Research Scholarship |

Regional/National presentations (resident)

1. 3/2023 Trembath H, Weighill D, Schrank Z, Thel H, Worth A, Morrison AB, Xu Y, Kearney JF, G Herrera G, **Yeh JJ** Towards a noninvasive blood test for molecular subtyping. AHPBA Annual Meeting March 9-12 2023 (Oral) AHPBA Annual Meeting March 9-12 2023 Miami FL
2. 3/2023 Kearney JF, Morrison AB, Maharry S, Peng X, Chan P, Trembath H, Maduekwe U, Calvo BF, Meyers MO, Kim HJ, **Yeh JJ**. Pancreatic Cancer Molecular Subtype Determines Benefit of FOLFIRINOX Chemotherapy. (Presidential Plenary) AHPBA Annual Meeting March 9-12 2023 Miami FL
3. 3/2022 Kearney JF, McCabe I, Morrison AB, Jenner M, Kuhlert PC, Weighill D, Peng X, Meyers MO, Kim HJ, Calvo BF, **Yeh JJ**. Tumor Stroma Crosstalk in Pancreatic Ductal Adenocarcinoma Is Molecular Subtype Dependent. (Oral) Society of Surgical Oncology Annual Meeting, , Dallas, TX.
4. 8/2021 Kearney JF, Kuhlert PC, Morrison AB, Maharry S, Leary J, Peng X, Kim HJ, Meyers MO, Calvo BF, Maduekwe U, **Yeh JJ**. Tumor ecosystem differences in 75 pancreatic ductal adenocarcinoma patients after neoadjuvant chemotherapy vs no neoadjuvant chemotherapy (Poster) International Hepato-Pancreato-Biliary Association Annual Meeting, April 2022, New York, NY

5. 8/2021 Kearney JF, Kuhlert PC, Morrison AB, Maharry S, Leary J, Peng X, Kim HJ, Meyers MO, Calvo BF, Maduekwe U, **Yeh JJ**. Tumor ecosystem differences in 75 pancreatic ductal adenocarcinoma patients after neoadjuvant chemotherapy vs no neoadjuvant chemotherapy (Oral) Americas Hepatobiliary Association Annual Meeting, Miami, FL
6. 3/2021 Kearney JF, Kuhlert PC, Morrison AB, Maharry S, Leary J, Peng X, Kim HJ, Meyers MO, Calvo BF, Maduekwe U, **Yeh JJ**. Tumor and Tumor Microenvironment Landscape after Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (Oral) Society of Surgical Oncology Annual Cancer Symposium, Virtual
7. 3/2019 Torphy RJ, Peng XL, Moffitt RA, **Yeh JJ**. Immune enrichment improves outcomes only in activated stroma subtype in patients (Plenary) Society of Surgical Oncology Annual Cancer Symposium, San Diego, CA
8. 3/2017 Black J (Oral, Award Winner) Southeastern Surgical Congress, Nashville TN
9. 3/2016 Becker C (Poster presentation) Society of Surgical Oncology Annual Cancer Symposium, Boston, MA
10. 3/2016 Caddell K (Poster presentation) Society of Surgical Oncology Annual Cancer Symposium, Boston, MA
11. 10/2015 Marayati R, **Yeh JJ**. Differentially expressed gene signature associated with metastasis and poor outcome in pancreatic cancer patients. (Oral presentation) American College of Surgeons Annual Meeting, Chicago, I
12. 3/2015 Marayati R, Whittlesey R, **Yeh JJ**. New circulating biomarker for patients with metastatic pancreatic cancer. (Oral presentation) Society of Surgical Oncology Annual Cancer Symposium, Houston, TX
13. 3/2015 Tignanelli CJ, Jajja MR, Stratford JS, Moffitt RM, Reuther R, Johnson GL, **Yeh JJ** Adaptive response of pancreatic ductal adenocarcinoma to single agent kinase inhibitor therapies. (Poster) Society of Surgical Oncology Annual Cancer Symposium, Houston, TX
14. 3/2015 Black J, Cotton T, Calvo B, Ollila DW, Kim L, **Yeh JJ** Safety of outpatient thyroidectomy. (Poster) Society of Surgical Oncology Annual Cancer Symposium, Houston, TX
15. 2/2015 Tignanelli CJ, Jajja MR, Stratford JS, Moffitt RM, Reuther R, Johnson GL, **Yeh JJ** PI3K and pan-Erb Inhibition overcomes ErbB cross-talk in pancreatic cancer (Oral presentation) Academic Surgical Congress National Meeting, Las Vegas, NV
16. 2/2015 Marayati R, Moffitt RM, **Yeh JJ** Patient-derived pancreatic cancer xenografts reflect patient tumor biology and predict outcome. (Oral presentation) Academic Surgical Congress National Meeting, Las Vegas, NV
17. 10/2014 Tignanelli CJ, Jajja MR, Stratford JS, Moffitt RM, Reuther R, Johnson GL, **Yeh JJ**. A rational approach for combination therapy selection in pancreatic cancer. (Oral presentation) American College of Surgeons Annual Meeting, San Francisco, CA
18. 5/2014 Tignanelli CJ, Jajja MR, Stratford JS, Moffitt RM, Reuther R, Johnson GL, **Yeh JJ**. Multiplexed kinase inhibitor beads identify multiple pathways of resistance to PI3K inhibition facilitating the rational selection of novel combination therapies in pancreatic cancer. (Poster) AACR Pancreatic Cancer: Innovations in Research and Treatment, New Orleans, LA
19. 3/2014 Tignanelli CJ, Jajja MR, Stratford JS, Moffitt RM, Reuther R, Johnson GL, **Yeh JJ**. Resistance to PI3K inhibition in pancreatic cancer is mediated through the ErBB pathway. (Poster) Society of Surgical Oncology Annual Cancer Symposium, Phoenix, AZ
20. 2/2014 Tignanelli CJ, Torphy RJ, Kamande J, Soper SA, **Yeh JJ** Method for high sensitivity *KRAS* mutation detection in circulating tumor cells. (Oral presentation) Academic Surgical Congress, San Diego, CA
21. 3/2014 Jajja MR, Herrera-Loweza SG, Reuther R, Johnson GL, **Yeh JJ** Identification of possible combination therapies for MEK inhibition in pancreatic cancer. (Oral presentation) Academic Surgical Congress, San Diego, CA

22. 2/2014 Cotton TM, Snavely A, Calvo BG, Amos KD, Hammett-Stabler CA, **Yeh JJ**. System changes to improve cost-effectiveness of standard intraoperative parathyroid hormone assays: location, location, location. (Poster) Southeastern Surgical Annual Scientific Meeting, Savannah, GA
23. 2/2014 Tignanelli CJ, Herrera Loeza SG, **Yeh JJ**. *KRAS* and *PI3K* mutation frequencies in patient derived xenograft (PDX) models of pancreatic and metastatic colorectal cancer are reflective of patient tumors and stable across passages. (Oral presentation) Southeastern Surgical Annual Scientific Meeting, Savannah, GA
24. 11/2013 Tignanelli CJ, Torphy RJ, Moffit RM, Kamande J, Soper SA, **Yeh JJ**. Circulating tumor cells as an early biomarker of treatment response in pancreatic ductal adenocarcinoma. (Poster) American Pancreatic Association Annual Meeting, Miami, FL
25. 10/2013 Tignanelli CJ, Torphy RJ, **Yeh JJ**. The PI3K inhibitor BKM120 inhibits growth of pancreatic ductal adenocarcinoma in vitro and in vivo. (Oral presentation) American College of Surgeons Annual Meeting, Washington, DC
26. 2/2013 Tignanelli CJ, Torphy RJ, Moffit RM, Kamande J, Soper SA, **Yeh JJ**. Isolation of circulating tumor cells from patient derived xenograft mouse models of pancreatic cancer. (Quickshot presentation) American Surgical Congress National Meeting, New Orleans, LA
27. 2/2013 Jajja MR, O'Neill A, Byrne JB, Napier M, DeSimone JS, **Yeh JJ** Electric field assisted delivery of gemcitabine is more effective than systemic delivery. (Oral presentation) Academic Surgical Congress, New Orleans, LA
28. 3/2010 Sweeting RS, Routh ED, Meyers MO, Long T, Frank JS, Amos K, Stitzenberg KB, Ollila DW, **Yeh JJ** Sentinel lymph node biopsy is a powerful predictor of recurrence for patients with cutaneous head and neck melanoma. (Poster) Society of Surgical Oncology Annual Cancer Symposium, St. Louis, MO
29. 1/2008 Samuel JC, Routh ED, Der CJ. **Yeh JJ**. ERK inhibition is not predictive of response to the MEK inhibitor AZD6244 in colorectal cancer. (Poster) American Society of Clinical Oncology Gastrointestinal Cancer Symposium, Orlando, FL

Fellows Awards and Presentations

Awards (fellow)

2011 Justin Baker, NC TraCs 2K grant

Local Presentations (fellow)

1. 6/2013 Circulating Tumor Cells (Department of Surgery Grand Rounds) University of North Carolina, Chapel Hill, NC

Regional/National Presentations (fellow)

1. 3/2018 Louie R, **Yeh JJ**. Residents/Fellows Case Presentation (Oral) Society of Surgical Oncology Annual Cancer Symposium, Chicago IL
2. 3/2018 Schmidt B, Moffitt RA, Rashid NU, Voltzke K, Herrera S, Volmar KE, Collins K, Kim HJ, **Yeh JJ**. Clinically usable molecular subtyping of pancreatic ductal adenocarcinoma from needle biopsies. (Oral) Society of Surgical Oncology Annual Cancer Symposium, Chicago IL
3. 3/2017 Schmidt B, Herrera S, Trembath Y, Greene K, **Yeh JJ**. A *KRAS* P53 P16 genetically engineered mouse model of pancreatic cancer. (Oral) Society of Surgical Oncology Annual Cancer Symposium, Seattle WA
4. 3/2014 Cader SR, Flate E, Heakal Y, Moffit RM, Kuan PF, Anderson JM, Hollingsworth MA, **Yeh JJ**. *BCAR3* is important in dissemination in pancreatic cancer. (Poster Grand Rounds) Society of Surgical Oncology Annual Cancer Symposium, Phoenix, AZ

5. 3/2013 Aufforth RD, Baker JJ, Witek MA, Kamande JW, Kim H, Kuan PF, Soper SA, **Yeh JJ**. Circulating Tumor Cells as a Possible Marker for Micrometastatic Disease in Patients with Localized Pancreatic Cancer (Poster) Society of Surgical Oncology 66th Annual Cancer Symposium, Washington, DC
6. 1/2013 Aufforth RD, Baker JJ, Witek MA, Kamande JW, Kim H, Kuan PF, Soper SA, **Yeh JJ**. Circulating Tumor Cells as a Possible Marker for Micrometastatic Disease in Patients with Localized Pancreatic Cancer (Poster) Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology, San Francisco, CA
7. 3/2012 Aufforth RD, Baker JJ, Auman JT, Eil R, McLeod H, Kim H, Meyers MO, Calvo BF, **Yeh JJ**. KRAS Mutation is a Poor Prognostic Factor in Patients Undergoing Hepatic Resection for Metastatic Colorectal Cancer (Poster) Society of Surgical Oncology 65th Annual Cancer Symposium, Orlando, FL